Want to see INIS full AI Analyst Report?
INIS Stock Chart & Stats
$0.06
>-$0.01(-1.97%)
At close: 4:00 PM EST
$0.06
>-$0.01(-1.97%)
Day’s Range― - ―
52-Week Range$0.05 - $0.11
Previous CloseN/A
Volume75.77K
Average Volume (3M)97.60K
Market Cap
$37.04M
Enterprise Value$44.48M
Total Cash (Recent Filing)$1.35M
Total Debt (Recent Filing)$8.79M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1723.63
Shares Outstanding529,130,400
10 Day Avg. Volume65,048
30 Day Avg. Volume97,599
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.74
Price to Sales (P/S)2.47
P/FCF Ratio375.15
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue3.64
Enterprise Value/Gross Profit8.05
Enterprise Value/Ebitda-31.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA TTM gross margin near 69% implies meaningful pricing power or low variable costs in isotope production. For a specialty nuclear-medicine supplier, sustained high gross margins support long-term profit recovery if operating expenses are controlled and allow room for investment in regulatory approvals and product quality.
Positive Operating Cash FlowReturn to positive operating cash flow shows the core business is generating cash, improving liquidity and reducing reliance on external funding. If sustained, this supports working capital, modest capex and debt service, and provides a structural foundation for stabilizing operations over the next several quarters.
Improved Capital-Structure FlexibilityAmendments that remove liens, extend maturities and add conversion features materially ease near-term liquidity and redemption pressure. These structural financing changes lengthen the runway and give management flexibility to execute operational improvements and regulatory milestones over multiple years.
Bears Say
Declining RevenueA nearly 25% TTM revenue drop weakens scale in a niche supply business and signals structural demand loss or competitive/contract issues. Sustained top-line deterioration undermines margin leveraging, makes fixed-cost absorption harder, and requires durable commercial fixes to restore growth.
Persistent Operating LossesChronic negative EBIT/EBITDA and large net losses mean the company cannot currently convert gross profits into operating profits. Over time this erodes equity returns, constrains reinvestment for regulatory compliance or new product development, and necessitates either sustained revenue recovery or deep cost restructuring.
Elevated Leverage & Balance-Sheet VolatilityHigh debt-to-equity and episodic spikes in leverage increase refinancing and liquidity risk, limiting strategic flexibility in a capital-intensive regulated industry. Even with recent extensions, elevated leverage raises default risk and constrains the firm's ability to fund necessary capex or navigate regulatory timelines.
International Isotopes News
INIS FAQ
What was International Isotopes’s price range in the past 12 months?
International Isotopes lowest stock price was $0.04 and its highest was $0.11 in the past 12 months.
What is International Isotopes’s market cap?
International Isotopes’s market cap is $37.04M.
When is International Isotopes’s upcoming earnings report date?
International Isotopes’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.
How were International Isotopes’s earnings last quarter?
Currently, no data Available
Is International Isotopes overvalued?
According to Wall Street analysts International Isotopes’s price is currently Overvalued.
Does International Isotopes pay dividends?
International Isotopes does not currently pay dividends.
What is International Isotopes’s EPS estimate?
International Isotopes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does International Isotopes have?
International Isotopes has 529,130,400 shares outstanding.
What happened to International Isotopes’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of International Isotopes?
Currently, no hedge funds are holding shares in INIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
International Isotopes
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
Technical Analysis
Ownership Overview
13.32% Insiders
<0.01% Other Institutional Investors
86.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---